← Back to Search

Iron Supplement

IV vs Oral Iron for Iron-Deficiency Anemia

Phase 3
Recruiting
Research Sponsored by Auerbach Hematology Oncology Associates P C
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trial will compare the efficacy of oral versus intravenous iron therapy for the treatment of iron deficiency anemia in the post-bariatric surgical patient.

Who is the study for?
This trial is for adults over 18 who've had Roux-en-Y Gastric Bypass or Vertical Sleeve Gastrectomy at least 3 months ago and are now facing iron deficiency anemia. It's not for those with iron utilization disorders, planned surgeries during the study, pregnant/nursing women, liver issues, multiple allergies, active infections, recent IV iron treatments or known hypersensitivity to the drugs tested.Check my eligibility
What is being tested?
The study compares oral ferrous sulfate tablets with intravenous (IV) Ferumoxytol in treating post-operative bariatric surgery patients with iron deficiency anemia. Participants will be randomly assigned to one of these two treatments and monitored for efficacy and speed of response over a period that includes a primary outcome measure at 6 weeks and follow-up at 12 months.See study design
What are the potential side effects?
Oral ferrous sulfate can cause gastric irritation, nausea, epigastric discomfort, constipation while IV Ferumoxytol may lead to infusion reactions. Side effects vary by individual; some might experience none while others could have more severe reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Clinical Global Impression - improvement scale (CGI-2) score at 6 weeks after treatment begins.
Change in hemoglobin concentration
Secondary outcome measures
Change in Transferrin saturation (TSAT) >19%
Change in ferritin > 20%
Quality of Life by visual linear analog scale (LASA)

Trial Design

2Treatment groups
Active Control
Group I: Oral IronActive Control4 Interventions
The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
Group II: IV IronActive Control4 Interventions
The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.

Find a Location

Who is running the clinical trial?

Auerbach Hematology Oncology Associates P CLead Sponsor
4 Previous Clinical Trials
336 Total Patients Enrolled
AMAG Pharmaceuticals, Inc.Industry Sponsor
43 Previous Clinical Trials
11,262 Total Patients Enrolled

Media Library

Ferrous sulfate tablets (Iron Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04268849 — Phase 3
Iron-Deficiency Anemia Research Study Groups: Oral Iron, IV Iron
Iron-Deficiency Anemia Clinical Trial 2023: Ferrous sulfate tablets Highlights & Side Effects. Trial Name: NCT04268849 — Phase 3
Ferrous sulfate tablets (Iron Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04268849 — Phase 3
Iron-Deficiency Anemia Patient Testimony for trial: Trial Name: NCT04268849 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being sought for this clinical trial?

"This is an active recruitment trial, according to the information available on clinicaltrials.gov. The study was posted on 2/27/2020, with the most recent update taking place on 2/16/2022."

Answered by AI

Could you please explain what intravenous iron is commonly used to treat?

"IV Iron is frequently used to remedy a vitamin a deficiency. Additionally, it is sometimes used to mitigate the effects of anemia, vitamin deficiency, and catarrh."

Answered by AI

Could you please give an estimate of how many people are participating in this clinical trial?

"That is correct, the clinicaltrials.gov website does show that this study is actively recruiting patients. This specific study was posted on February 27th, 2020 and was updated as recently as February 16th, 2022. Currently, they are looking to enroll 104 participants from a single site."

Answered by AI

When was the last time IV Iron was cleared by the FDA?

"IV Iron has been found to be safe in Phase 3 trials, meaning that it has undergone multiple rounds of testing with positive results."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
What site did they apply to?
Auerbach Hematology and Oncology
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I'm post bariatric with iron deficiency.
PatientReceived 2+ prior treatments
~20 spots leftby Apr 2025